Bumetanide and Antivert drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Bumetanide (bumetanide) and Antivert (meclizine hydrochloride). Common drug interactions include chronic kidney disease among females and chronic kidney disease among males.

The phase IV clinical study analyzes what interactions people have when they take Bumetanide and Antivert. It is created by eHealthMe based on reports of 29 people who take the same drugs from the FDA, and is updated regularly.

What is Bumetanide?

Bumetanide has active ingredients of bumetanide. It is often used in fluid retention. eHealthMe is studying from 20,532 Bumetanide users. Check the latest studies of Bumetanide.

What is Antivert?

Antivert has active ingredients of meclizine hydrochloride. It is often used in dizziness. eHealthMe is studying from 4,087 Antivert users. Check the latest studies of Antivert.

On Jul, 15, 2026

29 people who take Bumetanide and Antivert together, and have interactions are studied.

Bumetanide and Antivert drug interactions.

What are the common drug interactions of Bumetanide and Antivert, by gender? *:

female:

Chronic kidney disease
Hyperparathyroidism secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary)
Renal failure (kidney dysfunction)
Death
Nephrogenic anaemia (anaemia due to kidney disease)
Renal injury (kidney injury)
Tubulointerstitial nephritis (a form of nephritis affecting the interstitium of the kidneys surrounding the tubules)
Bacterial test positive
Drug hypersensitivity
Drug ineffective

male:

Chronic kidney disease
Renal failure (kidney dysfunction)
Haemoglobin decreased
Hereditary neuropathic amyloidosis (hereditary- diseases resulting from abnormal deposition of certain proteins (amyloid) in various bodily areas by problems with signals from the nerves)
Hyperparathyroidism secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary)
Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
Platelet count decreased
Protein urine present
Red blood cells urine positive
Urinary casts

What are the common drug interactions of Bumetanide and Antivert, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Chronic kidney disease
Renal failure (kidney dysfunction)
Renal injury (kidney injury)
Hyperparathyroidism secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary)
Nephrogenic anaemia (anaemia due to kidney disease)
Tubulointerstitial nephritis (a form of nephritis affecting the interstitium of the kidneys surrounding the tubules)
Death
Gastrooesophageal reflux disease (stomach contents (food or liquid) leak backwards from the stomach into the oesophagus)
Hyperkalaemia (damage to or disease of the kidney)
Abscess intestinal (collections of pus-intestinal)

60+:

Chronic kidney disease
Drug hypersensitivity
Death
Decreased appetite
Dry mouth
Dyspnoea (difficult or laboured respiration)
Fatigue (feeling of tiredness)
Gastritis (inflammation of stomach)
Gastrooesophageal reflux disease (stomach contents (food or liquid) leak backwards from the stomach into the oesophagus)
Glomerular filtration rate decreased

What are the existing conditions these people have? *

Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 8 people, 27.59%
Infection: 5 people, 17.24%
Nausea (feeling of having an urge to vomit): 4 people, 13.79%
Hereditary Neuropathic Amyloidosis (hereditary- diseases resulting from abnormal deposition of certain proteins (amyloid) in various bodily areas by problems with signals from the nerves): 4 people, 13.79%
Constipation: 4 people, 13.79%
Small Intestine Carcinoma (cancer tumour of small intestine): 3 people, 10.34%
Carcinoid Tumor Of The Small Bowel: 3 people, 10.34%
Swelling: 2 people, 6.90%
Rickets (softening of bones): 2 people, 6.90%
Pain: 2 people, 6.90%

* Approximation only. Some reports may have incomplete information.

Do you take Bumetanide and Antivert?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously